WallStreetZenWallStreetZen

NASDAQ: OVID
Ovid Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OVID

Based on 3 analysts offering 12 month price targets for Ovid Therapeutics Inc

Min Forecast
$1.50+59.57%
Avg Forecast
$2.83+201.38%
Max Forecast
$4.00+325.53%

Should I buy or sell OVID stock?

Based on 3 analysts offering ratings for Ovid Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OVID's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates OVID as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their OVID stock forecasts and price targets.

OVID stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-27
lockedlocked$00.00+00.00%2025-03-24
lockedlocked$00.00+00.00%2025-03-12

1 of 1

Forecast return on equity

Is OVID forecast to generate an efficient return?

Company
-130.86%
Industry
127.2%
Market
-48.11%
OVID's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OVID forecast to generate an efficient return on assets?

Company
-94.29%
Industry
47.5%
OVID is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OVID earnings per share forecast

What is OVID's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
-$0.60
Avg 3 year Forecast
-$0.86

OVID revenue forecast

What is OVID's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$5.2M-21.56%
Avg 2 year Forecast
$536.0k-91.94%
Avg 3 year Forecast
$430.0k-93.53%

OVID vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OVID$0.94$2.83+201.38%Strong Buy
ABVC$2.85N/AN/A
IRD$1.11$6.33+470.54%Strong Buy
INKT$14.70$35.00+138.10%Buy
RPTX$1.53$5.00+226.80%Buy
View Top Biotech Stocks

Ovid Therapeutics Stock Forecast FAQ

Is Ovid Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: OVID) stock is to Strong Buy OVID stock.

Out of 3 analysts, 1 (33.33%) are recommending OVID as a Strong Buy, 2 (66.67%) are recommending OVID as a Buy, 0 (0%) are recommending OVID as a Hold, 0 (0%) are recommending OVID as a Sell, and 0 (0%) are recommending OVID as a Strong Sell.

If you're new to stock investing, here's how to buy Ovid Therapeutics stock.

What is OVID's earnings growth forecast for 2025-2027?

(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Ovid Therapeutics's earnings in 2025 is -$38,178,000.On average, 5 Wall Street analysts forecast OVID's earnings for 2025 to be -$37,688,042, with the lowest OVID earnings forecast at -$48,354,470, and the highest OVID earnings forecast at -$31,999,281. On average, 5 Wall Street analysts forecast OVID's earnings for 2026 to be -$42,665,708, with the lowest OVID earnings forecast at -$54,043,231, and the highest OVID earnings forecast at -$28,443,806.

In 2027, OVID is forecast to generate -$60,919,521 in earnings, with the lowest earnings forecast at -$71,820,609 and the highest earnings forecast at -$46,221,184.

What is OVID's revenue growth forecast for 2025-2027?

(NASDAQ: OVID) Ovid Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.

Ovid Therapeutics's revenue in 2025 is $6,651,000.On average, 4 Wall Street analysts forecast OVID's revenue for 2025 to be $370,978,335, with the lowest OVID revenue forecast at $40,532,423, and the highest OVID revenue forecast at $504,877,549. On average, 3 Wall Street analysts forecast OVID's revenue for 2026 to be $38,114,700, with the lowest OVID revenue forecast at $28,443,806, and the highest OVID revenue forecast at $49,776,660.

In 2027, OVID is forecast to generate $30,577,091 in revenue, with the lowest revenue forecast at $24,888,330 and the highest revenue forecast at $36,265,852.

What is OVID's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OVID) forecast ROA is -94.29%, which is lower than the forecast US Biotechnology industry average of 47.5%.

What is OVID's Price Target?

According to 3 Wall Street analysts that have issued a 1 year OVID price target, the average OVID price target is $2.83, with the highest OVID stock price forecast at $4.00 and the lowest OVID stock price forecast at $1.50.

On average, Wall Street analysts predict that Ovid Therapeutics's share price could reach $2.83 by May 27, 2026. The average Ovid Therapeutics stock price prediction forecasts a potential upside of 201.38% from the current OVID share price of $0.94.

What is OVID's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: OVID) Ovid Therapeutics's current Earnings Per Share (EPS) is -$0.53. On average, analysts forecast that OVID's EPS will be -$0.53 for 2025, with the lowest EPS forecast at -$0.68, and the highest EPS forecast at -$0.45. On average, analysts forecast that OVID's EPS will be -$0.60 for 2026, with the lowest EPS forecast at -$0.76, and the highest EPS forecast at -$0.40. In 2027, OVID's EPS is forecast to hit -$0.86 (min: -$1.01, max: -$0.65).

What is OVID's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OVID) forecast ROE is -130.86%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.